(PharmaNewsWire.Com, August 28, 2017 ) Middle east and Africa Checkpoint Inhibitors Market was worth USD 610 million in 2016 and is expected to reach USD 1590 million by 2021 with a CAGR of 27.19 %.
Checkpoint Inhibitor Market are drugs used in Immunotherapy. They are generally made up of antibodies that lead an immune system attack on cancer cells. T-cells launches an attack when it detects infected or Cancerous. Immune system uses a series of molecules called checkpoint molecules to protect normal cells from attack. Cancer cells use these Checkpoints to escape T-cells by arraying themselves with Normal Cells. Checkpoint Inhibitors block these proteins on cancer cells which lets T-Cells launch an attack on Cancer cells.
Increasing funding and government support towards developing new drugs and rising Prevalence of cancer globally are some of the factors driving the growth of the market. However, high R&D expense activities is one of the major factors responsible for restricting the growth of the market.
Middle east and Africa Checkpoint Inhibitors Market is categorized based on Drug type and Application. Based on Drug type, market is segmented into PD-L1 inhibitors, PD-1 inhibitors, CTLA-4, Chimeric Antigen Receptor T-cell, and Others. Based on Application, the market is segmented into Lung cancer, Blood cancer, Renal cancer, Bladder Cancer, Melanoma, Hodgkin lymphoma, Others. CTLA-4 segment holds the largest share accounting for almost 94 % of the overall market.
However, this segment is expected to drop some of its market share to PD-1 inhibitors segment during the mentioned period as majority of new treatments are based on PD-1 inhibitors. Geographically, market is further segmented into Middle east and Africa
Some of the major players in the Middle east and Africa checkpoint inhibitors market include Merck & Co., Inc., Roche, AstraZeneca, Bristol-Myers Squibb, Ono Pharmaceutical Co., Ltd., Novartis International AG, Juno Therapeutics, and Kite Pharma.
Market Data Forecast is a firm working in the area of market research and business intelligence. With rich experience in research across various business domains, we cater to the needs of both individual and corporate clients. Our analyst team comprises expert professionals in market research, who with their collective knowledge and skillset dedicatedly serve clients from various industries and regions.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
